Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001161697-21-000280
Filing Date
2021-05-21
Accepted
2021-05-21 15:33:13
Documents
40
Period of Report
2021-03-31

Document Format Files

Seq Description Document Type Size
1 FORM 10-Q QUARTERLY REPORT FOR 03-31-2021 form_10-q.htm 10-Q 480186
2 RULE 13(A)-14(A)/15(D)-14(A) CERTIFICATION ex_31-1.htm EX-31 5683
3 SECTION 1350 CERTIFICATION ex_32-1.htm EX-32 3582
4 GRAPHIC angiosoma-logo.jpg GRAPHIC 12338
  Complete submission text file 0001161697-21-000280.txt   2142021

Data Files

Seq Description Document Type Size
5 XBRL INSTANCE FILE soan-20210331.xml EX-101.INS 263970
6 XBRL SCHEMA FILE soan-20210331.xsd EX-101.SCH 20878
7 XBRL CALCULATION FILE soan-20210331_cal.xml EX-101.CAL 30824
8 XBRL DEFINITION FILE soan-20210331_def.xml EX-101.DEF 118730
9 XBRL LABEL FILE soan-20210331_lab.xml EX-101.LAB 173417
10 XBRL PRESENTATION FILE soan-20210331_pre.xml EX-101.PRE 153601
Mailing Address 719 JADWIN AVENUE RICHLAND WA 99352
Business Address 719 JADWIN AVENUE RICHLAND WA 99352 832-781-8521
AngioSoma, Inc. (Filer) CIK: 0001502152 (see all company filings)

EIN.: 273480481 | State of Incorp.: WY | Fiscal Year End: 0930
Type: 10-Q | Act: 34 | File No.: 000-55072 | Film No.: 21948775
SIC: 2834 Pharmaceutical Preparations